Author

D. Perea

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Grau-Exposito· 3 shared M. Genesca· 3 shared M. J. Buzon· 3 shared A. Dolinar· 1 shared A. Peralta-Garcia· 1 shared A. Serrano-Mollar· 1 shared A. Vergara· 1 shared B. Trinite· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

J. Grau-Exposito

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

J. Kladnik, A. Dolinar, J. Kljun, D. Perea, J. Grau-Exposito, M. Genesca, M. Novinec, M. J. Buzon, I. Turel

bioRxiv · Mar 3, 2022Biochemistry

Entrectinib - a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells

A. Peralta-Garcia, M. Torrens-Fontanals, T. M. Stepniewski, J. Grau-Exposito, D. Perea, V. Ayinampudi, M. Waldhoer, M. Zimmermann, M. J. Buzon, M. Genesca, J. Selent

This study identifies entrectinib as a potential antiviral drug against SARS-CoV-2 using drug repurposing, virtual screening, and in vitro assays in Human Lung Tissue cells.

bioRxiv · Sep 7, 2021Cell Biology

Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells

J. Grau-Exposito, D. Perea, M. Suppi, N. Massana, A. Vergara, M. J. Soler, J. Blanco, B. Trinite, J. Garcia-Perez, J. Alcami, A. Serrano-Mollar, J. Rosado, V. Falco, M. Genesca, M. J. Buzon

This paper develops a method using primary human lung tissue cells to study SARS-CoV-2 entry, inflammation, and therapeutics, identifying new drug candidates and showing interferons do not modulate ACE2 expression.

bioRxiv · Apr 21, 2021Microbiology